ZC3H3

Summary

ZC3H3 (zinc finger CCCH-type containing 3, HGNC:28972) is a protein-coding gene on chromosome 8q24.3, encoding Zinc finger CCCH domain-containing protein 3 (Q8IXZ2). Required for the export of polyadenylated mRNAs from the nucleus. It is a selective cancer dependency (DepMap: 16.4% of cell lines).

Predicted to enable DNA binding activity; R-SMAD binding activity; and zinc ion binding activity. Predicted to be involved in mRNA transport. Predicted to act upstream of or within mRNA 3’-end processing and positive regulation of activin receptor signaling pathway. Located in nucleus.

Source: NCBI Gene 23144 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 246 total
• Phenotypes (HPO): 2
• Cancer dependency (DepMap): dependent in 16.4% of screened cell lines
• MANE Select transcript: NM_015117

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28972
Approved symbol	ZC3H3
Name	zinc finger CCCH-type containing 3
Location	8q24.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0150
Ensembl gene	ENSG00000014164
Ensembl biotype	protein_coding
OMIM	618640
Entrez	23144

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000262577, ENST00000528401, ENST00000875766, ENST00000932295, ENST00000932296

RefSeq mRNA: 1 — MANE Select: NM_015117 NM_015117

CCDS: CCDS6402

Canonical transcript exons

ENST00000262577 — 12 exons

Exon	Start	End
ENSE00000487293	143536257	143536453
ENSE00000876572	143541376	143541447
ENSE00001140266	143465717	143465848
ENSE00001140276	143468209	143468278
ENSE00001140283	143468382	143468540
ENSE00001140289	143468617	143468659
ENSE00001140296	143475398	143475585
ENSE00001209896	143507746	143507899
ENSE00001209902	143538003	143539320
ENSE00001254909	143440936	143441120
ENSE00001254986	143440041	143440363
ENSE00001338604	143437659	143438087

Expression profiles

Bgee: expression breadth ubiquitous, 184 present calls, max score 90.16.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.9028 / max 57.0692, expressed in 1769 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
95477	8.8210	1769
95478	0.0648	18
95470	0.0170	8

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	90.16	gold quality
oocyte	CL:0000023	88.71	gold quality
secondary oocyte	CL:0000655	86.50	gold quality
granulocyte	CL:0000094	86.09	gold quality
gastrocnemius	UBERON:0001388	85.97	gold quality
endometrium epithelium	UBERON:0004811	85.93	silver quality
hindlimb stylopod muscle	UBERON:0004252	85.63	gold quality
small intestine Peyer’s patch	UBERON:0003454	84.94	gold quality
mucosa of transverse colon	UBERON:0004991	84.68	gold quality
apex of heart	UBERON:0002098	84.24	gold quality
lower esophagus mucosa	UBERON:0035834	84.23	gold quality
muscle of leg	UBERON:0001383	84.19	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.45	gold quality
skin of leg	UBERON:0001511	83.32	gold quality
right testis	UBERON:0004534	83.01	gold quality
left testis	UBERON:0004533	82.95	gold quality
omental fat pad	UBERON:0010414	82.95	gold quality
peritoneum	UBERON:0002358	82.83	gold quality
transverse colon	UBERON:0001157	82.57	gold quality
lower esophagus	UBERON:0013473	82.49	gold quality
lower esophagus muscularis layer	UBERON:0035833	82.49	gold quality
skin of abdomen	UBERON:0001416	82.45	gold quality
right lobe of thyroid gland	UBERON:0001119	82.44	gold quality
small intestine	UBERON:0002108	82.04	gold quality
popliteal artery	UBERON:0002250	81.92	gold quality
left adrenal gland cortex	UBERON:0035825	81.92	gold quality
muscle layer of sigmoid colon	UBERON:0035805	81.91	gold quality
tibial artery	UBERON:0007610	81.90	gold quality
left uterine tube	UBERON:0001303	81.88	gold quality
left lobe of thyroid gland	UBERON:0001120	81.85	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-5061	yes	15.52
E-ANND-3	no	2.53

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

31 targeting ZC3H3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4500	99.99	72.72	2367
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-5695	99.41	67.48	1047
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-6848-5P	98.81	65.49	1126
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-7111-3P	97.80	66.75	1467
HSA-MIR-6781-3P	97.44	66.85	970
HSA-MIR-6501-5P	97.41	68.24	712
HSA-MIR-6131	97.22	66.72	960
HSA-MIR-2682-3P	97.10	66.16	840
HSA-MIR-1226-5P	96.50	65.28	643

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 16.4% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 1)

• three additional proteins required for Poly(A) Tail eXosome Targeting (PAXT) function: ZC3H3, RBM26 and RBM27 along with the known PAXT-associated protein, PABPN1, were identified. (PMID:31950173)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	zc3h3	ENSDARG00000090751
mus_musculus	Zc3h3	ENSMUSG00000075600
rattus_norvegicus	Zc3h3	ENSRNOG00000007684
drosophila_melanogaster	ZC3H3	FBGN0035900

Paralogs (2): CPSF4 (ENSG00000160917), CPSF4L (ENSG00000187959)

Protein

Protein identifiers

Zinc finger CCCH domain-containing protein 3 — Q8IXZ2 (reviewed: Q8IXZ2)

Alternative names: Smad-interacting CPSF-like factor

All UniProt accessions (2): Q8IXZ2, H0YEY2

UniProt curated annotations — full annotation on UniProt →

Function. Required for the export of polyadenylated mRNAs from the nucleus. Enhances ACVR1B-induced SMAD-dependent transcription. Binds to single-stranded DNA but not to double-stranded DNA in vitro. Involved in RNA cleavage.

Subunit / interactions. Interacts with SMAD1, SMAD3, SMAD4, CPSF2 and CPSF3.

Subcellular location. Nucleus.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8IXZ2-1	1	yes
Q8IXZ2-2	2

RefSeq proteins (1): NP_055932* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000571	Znf_CCCH	Domain
IPR036855	Znf_CCCH_sf	Homologous_superfamily

Pfam: PF00642

UniProt features (43 total): sequence variant 16, compositionally biased region 9, region of interest 6, zinc finger region 5, modified residue 3, splice variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IXZ2-F1	52.45	0.12

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 408, 918, 920

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9930044	Nuclear RNA decay

MSigDB gene sets: 100 (showing top): SHEPARD_BMYB_MORPHOLINO_UP, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_REGULATION_OF_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY, MODULE_256, GOBP_MRNA_3_END_PROCESSING, GOBP_NUCLEOBASE_CONTAINING_COMPOUND_TRANSPORT, LIAO_METASTASIS, GOBP_ACTIVIN_RECEPTOR_SIGNALING_PATHWAY, GOMF_SMAD_BINDING, MODULE_333, GOBP_RNA_LOCALIZATION, GOBP_POSITIVE_REGULATION_OF_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY, GOBP_REGULATION_OF_ACTIVIN_RECEPTOR_SIGNALING_PATHWAY, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_UP, REACTOME_METABOLISM_OF_RNA

GO Biological Process (3): mRNA 3’-end processing (GO:0031124), positive regulation of activin receptor signaling pathway (GO:0032927), mRNA transport (GO:0051028)

GO Molecular Function (5): DNA binding (GO:0003677), zinc ion binding (GO:0008270), R-SMAD binding (GO:0070412), SMAD binding (GO:0046332), metal ion binding (GO:0046872)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), mRNA cleavage and polyadenylation specificity factor complex (GO:0005847)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
mRNA processing	1
RNA 3’-end processing	1
activin receptor signaling pathway	1
regulation of activin receptor signaling pathway	1
positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
RNA transport	1
nucleic acid binding	1
transition metal ion binding	1
SMAD binding	1
protein binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
mRNA cleavage factor complex	1

Protein interactions and networks

STRING

1032 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZC3H3	VIRMA	Q69YN4	718
ZC3H3	RBM15	Q96T37	695
ZC3H3	RBM26	Q5T8P6	581
ZC3H3	RBM15B	Q8NDT2	581
ZC3H3	TMEM276	P0DTL5	572
ZC3H3	XKR7	Q5GH72	501
ZC3H3	RBM27	Q9P2N5	469
ZC3H3	ZFC3H1	O60293	464
ZC3H3	TIGD5	Q53EQ6	435
ZC3H3	EXOSC4	Q9NPD3	410
ZC3H3	MPHOSPH6	Q99547	408
ZC3H3	CRACDL	Q6NV74	403
ZC3H3	MRPL12	P52815	396
ZC3H3	EXOSC1	Q9Y3B2	391
ZC3H3	DIPK1A	Q5T7M9	390

IntAct

54 interactions, top by confidence:

A	B	Type	Score
CTBP2	ZNF217	psi-mi:“MI:0914”(association)	0.690
CACNG5	ZNF316	psi-mi:“MI:0914”(association)	0.530
LTBR	ZNF724	psi-mi:“MI:0914”(association)	0.530
MTMR9	CENPF	psi-mi:“MI:0914”(association)	0.530
PNMA2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
TRMT1	ZC3H3	psi-mi:“MI:0915”(physical association)	0.400
Anapc13	ANAPC15	psi-mi:“MI:0914”(association)	0.350
KIF3C	ZC3H3	psi-mi:“MI:0914”(association)	0.350
PTTG1	PMS1	psi-mi:“MI:0914”(association)	0.350
LLGL2	RBBP6	psi-mi:“MI:0914”(association)	0.350
THOC1	TARS3	psi-mi:“MI:0914”(association)	0.350
Ddb1		psi-mi:“MI:0914”(association)	0.350
Set	ZKSCAN1	psi-mi:“MI:0914”(association)	0.350
ZFC3H1	UNC119B	psi-mi:“MI:0914”(association)	0.350
SETD1B	WBP4	psi-mi:“MI:0914”(association)	0.350
Klc3	KLC1	psi-mi:“MI:0914”(association)	0.350
Dnaaf5	TPRN	psi-mi:“MI:0914”(association)	0.350
MIDEAS	SEC16A	psi-mi:“MI:0914”(association)	0.350
MZT1	ZC3H18	psi-mi:“MI:0914”(association)	0.350
LGALS3BP	CEP290	psi-mi:“MI:0914”(association)	0.350
ZNRD2	KRBA1	psi-mi:“MI:0914”(association)	0.350
APP	ZNF724	psi-mi:“MI:0914”(association)	0.350
CTDSP2	TBC1D4	psi-mi:“MI:0914”(association)	0.350
ZC3H3	ANKHD1	psi-mi:“MI:0914”(association)	0.350
APOBEC3D	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
NKAPD1	CASC3	psi-mi:“MI:0914”(association)	0.350
IKZF5	PEX14	psi-mi:“MI:0914”(association)	0.350
PIPSL	C1orf226	psi-mi:“MI:0914”(association)	0.350

BioGRID (376): ZC3H3 (Affinity Capture-RNA), ZC3H3 (Affinity Capture-RNA), ZC3H3 (Affinity Capture-MS), LARP7 (Affinity Capture-MS), RPL26L1 (Affinity Capture-MS), NIP7 (Affinity Capture-MS), NOP10 (Affinity Capture-MS), RPF1 (Affinity Capture-MS), RBM28 (Affinity Capture-MS), POP1 (Affinity Capture-MS), DDX24 (Affinity Capture-MS), MRPS9 (Affinity Capture-MS), FTSJ3 (Affinity Capture-MS), MRPS26 (Affinity Capture-MS), DDX21 (Affinity Capture-MS)

ESM2 similar proteins: A2BDC9, D3ZAP3, O08999, O35806, O60303, P04370, P24054, P53814, Q00918, Q09101, Q13438, Q14766, Q14767, Q28019, Q2Q0I9, Q3MHX6, Q4ZHG4, Q569E4, Q5BIR3, Q5R7R7, Q5RD34, Q5RKH6, Q5TCY1, Q5VUB5, Q5XI62, Q6A065, Q6WRH9, Q6ZPY7, Q7Z7G0, Q80U49, Q86UR5, Q8BJS7, Q8BSD5, Q8C8N3, Q8CG19, Q8CHP0, Q8IXZ2, Q8K2C7, Q91Z96, Q92615

Diamond homologs: O74823, Q8CHP0, Q8IXZ2, Q3ED78

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

246 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	199
Likely benign	26
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

4083 predictions. Top by Δscore:

Variant	Effect	Δscore
8:143465713:TCA:T	donor_loss	1.0000
8:143465715:A:AC	donor_gain	1.0000
8:143465715:A:T	donor_loss	1.0000
8:143465716:C:CC	donor_gain	1.0000
8:143468205:TCAC:T	donor_loss	1.0000
8:143468206:CACCT:C	donor_loss	1.0000
8:143468207:A:C	donor_loss	1.0000
8:143468208:CCTT:C	donor_gain	1.0000
8:143468288:C:CT	acceptor_gain	1.0000
8:143468378:GCACC:G	donor_loss	1.0000
8:143468379:CA:C	donor_loss	1.0000
8:143468381:C:T	donor_loss	1.0000
8:143468401:T:A	donor_gain	1.0000
8:143468536:CCCGG:C	acceptor_gain	1.0000
8:143468537:CCGG:C	acceptor_gain	1.0000
8:143468537:CCGGC:C	acceptor_gain	1.0000
8:143468538:CGG:C	acceptor_gain	1.0000
8:143468538:CGGC:C	acceptor_gain	1.0000
8:143468539:GG:G	acceptor_gain	1.0000
8:143468539:GGC:G	acceptor_loss	1.0000
8:143468541:C:CC	acceptor_gain	1.0000
8:143468541:CT:C	acceptor_loss	1.0000
8:143475393:CTCAC:C	donor_loss	1.0000
8:143475396:ACCTG:A	donor_loss	1.0000
8:143475584:ACCT:A	acceptor_loss	1.0000
8:143475585:CCT:C	acceptor_loss	1.0000
8:143475586:C:CC	acceptor_gain	1.0000
8:143475586:CTGCA:C	acceptor_loss	1.0000
8:143475587:T:A	acceptor_loss	1.0000
8:143507898:CG:C	acceptor_gain	1.0000

AlphaMissense

6045 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:143465734:A:G	C764R	1.000
8:143465747:G:C	F759L	1.000
8:143465747:G:T	F759L	1.000
8:143465749:A:G	F759L	1.000
8:143465758:A:G	C756R	1.000
8:143465800:A:G	C742R	1.000
8:143465813:G:C	C737W	1.000
8:143465839:A:G	C729R	1.000
8:143468241:A:G	C715R	1.000
8:143468387:G:C	C700W	1.000
8:143468388:C:T	C700Y	1.000
8:143468389:A:G	C700R	1.000
8:143441050:C:G	C793S	0.999
8:143441051:A:T	C793S	0.999
8:143441095:C:G	C778S	0.999
8:143441096:A:G	C778R	0.999
8:143441096:A:T	C778S	0.999
8:143441119:C:G	C770S	0.999
8:143441120:A:G	C770R	0.999
8:143441120:A:T	C770S	0.999
8:143465732:G:C	C764W	0.999
8:143465733:C:G	C764S	0.999
8:143465733:C:T	C764Y	0.999
8:143465734:A:T	C764S	0.999
8:143465748:A:C	F759C	0.999
8:143465748:A:G	F759S	0.999
8:143465756:G:C	C756W	0.999
8:143465757:C:A	C756F	0.999
8:143465757:C:G	C756S	0.999
8:143465757:C:T	C756Y	0.999

dbSNP variants (sampled 300 via entrez): RS1000017760 (8:143455187 G>A), RS1000019482 (8:143517660 G>A), RS1000026970 (8:143530204 C>T), RS1000065577 (8:143475063 T>C), RS1000069540 (8:143439916 G>A,C), RS1000078780 (8:143442969 AG>A), RS1000127776 (8:143466701 T>C), RS1000131769 (8:143478372 C>T), RS1000173128 (8:143481025 C>T), RS1000231435 (8:143542486 C>T), RS1000231949 (8:143445813 G>A), RS1000234521 (8:143488789 G>C), RS1000246067 (8:143488538 C>A,G), RS1000282194 (8:143519964 C>G), RS1000318626 (8:143449375 C>T)

Disease associations

OMIM: gene MIM:618640 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): neutropenia (MONDO:0001475), lymphopenia (MONDO:0003783)

Orphanet (0):

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0001875	Decreased total neutrophil count
HP:0001888	Decreased total lymphocyte count

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009531_8	Body fat percentage	5.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007800	body fat percentage

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008231	Lymphopenia	C15.378.243.750.605; C15.378.553.546.605; C20.673.627
D009503	Neutropenia	C15.378.243.750.184.564; C15.378.553.546.184.564

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression	3
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression	2
Benzo(a)pyrene	affects methylation, decreases expression	2
Valproic Acid	affects cotreatment, increases expression, increases methylation	2
Aflatoxin B1	affects expression, affects methylation	2
FR900359	decreases phosphorylation	1
TAK-243	increases sumoylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
terbufos	increases methylation	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
cupric chloride	increases expression	1
abrine	increases expression	1
Decitabine	decreases expression, affects reaction	1
Sunitinib	decreases expression	1
Caffeine	decreases phosphorylation	1
Fonofos	increases methylation	1
Fluorouracil	affects expression	1
Hydralazine	affects cotreatment, increases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Parathion	increases methylation	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases methylation	1
Cyclosporine	decreases expression	1
Cadmium Chloride	increases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

199 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00030758	PHASE4	UNKNOWN	Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
NCT00125723	PHASE4	COMPLETED	FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
NCT00194857	PHASE4	TERMINATED	Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin
NCT00257790	PHASE4	COMPLETED	The Tobramycin Study
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00686543	PHASE4	COMPLETED	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
NCT01086878	PHASE4	COMPLETED	Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
NCT01114165	PHASE4	COMPLETED	Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients
NCT01135589	PHASE4	UNKNOWN	Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation
NCT01571518	PHASE4	UNKNOWN	Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy
NCT02621905	PHASE4	COMPLETED	Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg
NCT02967341	PHASE4	UNKNOWN	Blood Draw Validation for Ciprofloxacin Pharmacokinetic Research in Pediatric Cancer Patients
NCT04009941	PHASE4	COMPLETED	Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
NCT04904614	PHASE4	COMPLETED	Letermovir Use in Heart Transplant Recipients
NCT05626530	PHASE4	RECRUITING	Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
NCT06145321	PHASE4	ACTIVE_NOT_RECRUITING	Continuous Versus Bolus Administration of G-CSF in Children With Cancer
NCT00001338	PHASE3	COMPLETED	A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
NCT00001646	PHASE3	COMPLETED	Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
NCT00002658	PHASE3	UNKNOWN	Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
NCT00002719	PHASE3	COMPLETED	Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
NCT00003739	PHASE3	COMPLETED	Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy
NCT00020865	PHASE3	UNKNOWN	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
NCT00035594	PHASE3	COMPLETED	Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
NCT00044486	PHASE3	COMPLETED	Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
NCT00107081	PHASE3	TERMINATED	Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of Oral Antibiotics in an Outpatient Setting
NCT00445497	PHASE3	UNKNOWN	Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
NCT00529282	PHASE3	TERMINATED	A Study of Ceftobiprole in Patients With Fever and Neutropenia.
NCT00627393	PHASE3	COMPLETED	Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
NCT00770172	PHASE3	COMPLETED	G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
NCT00784368	PHASE3	COMPLETED	A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
NCT00806351	PHASE3	TERMINATED	An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
NCT00911170	PHASE3	COMPLETED	PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
NCT01307579	PHASE3	COMPLETED	Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
NCT01371656	PHASE3	COMPLETED	Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
NCT01560195	PHASE3	UNKNOWN	A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
NCT01611051	PHASE3	COMPLETED	A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
NCT02238873	PHASE3	UNKNOWN	Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
NCT02414581	PHASE3	COMPLETED	Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7%
NCT02643420	PHASE3	COMPLETED	SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
NCT02872103	PHASE3	COMPLETED	Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy